CA3043938A1 - Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof - Google Patents

Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof Download PDF

Info

Publication number
CA3043938A1
CA3043938A1 CA3043938A CA3043938A CA3043938A1 CA 3043938 A1 CA3043938 A1 CA 3043938A1 CA 3043938 A CA3043938 A CA 3043938A CA 3043938 A CA3043938 A CA 3043938A CA 3043938 A1 CA3043938 A1 CA 3043938A1
Authority
CA
Canada
Prior art keywords
optionally substituted
compound
alkyl
group
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3043938A
Other languages
English (en)
French (fr)
Inventor
Kyle W. H. Chan
Paul E. Erdman
Leah Fung
Frank Mercurio
Robert Sullivan
Eduardo Torres
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioTheryX Inc
Original Assignee
BioTheryX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioTheryX Inc filed Critical BioTheryX Inc
Publication of CA3043938A1 publication Critical patent/CA3043938A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA3043938A 2016-12-21 2017-12-19 Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof Abandoned CA3043938A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662437400P 2016-12-21 2016-12-21
US62/437,400 2016-12-21
US201762485563P 2017-04-14 2017-04-14
US62/485,563 2017-04-14
US201762538203P 2017-07-28 2017-07-28
US62/538,203 2017-07-28
PCT/US2017/067353 WO2018118947A1 (en) 2016-12-21 2017-12-19 Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof

Publications (1)

Publication Number Publication Date
CA3043938A1 true CA3043938A1 (en) 2018-06-28

Family

ID=60991575

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3043938A Abandoned CA3043938A1 (en) 2016-12-21 2017-12-19 Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof

Country Status (13)

Country Link
US (4) US10040804B2 (https=)
EP (1) EP3559005A1 (https=)
JP (1) JP2020504711A (https=)
KR (1) KR20190093205A (https=)
CN (1) CN110099907A (https=)
AU (1) AU2017382176A1 (https=)
CA (1) CA3043938A1 (https=)
IL (1) IL267323A (https=)
MX (1) MX387646B (https=)
RU (1) RU2771166C2 (https=)
TW (2) TWI756957B (https=)
WO (1) WO2018118947A1 (https=)
ZA (1) ZA201903479B (https=)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CA3043938A1 (en) 2016-12-21 2018-06-28 Biotheryx, Inc. Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof
EP4717317A2 (en) 2017-06-20 2026-04-01 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
CN111278816B (zh) 2017-09-04 2024-03-15 C4医药公司 二氢喹啉酮
CN118108706A (zh) 2017-09-04 2024-05-31 C4医药公司 戊二酰亚胺
CN118206529A (zh) 2017-09-04 2024-06-18 C4医药公司 二氢苯并咪唑酮
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
JP2021519337A (ja) 2018-03-26 2021-08-10 シー4 セラピューティクス, インコーポレイテッド Ikarosの分解のためのセレブロン結合剤
EP3774815A1 (en) * 2018-03-30 2021-02-17 Biotheryx Inc. Thienopyrimidinone compounds
CN119751456A (zh) 2018-04-16 2025-04-04 C4医药公司 螺环化合物
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
CN112601751B (zh) * 2018-06-13 2024-04-02 拜欧斯瑞克斯公司 稠合噻吩化合物
MX2021001957A (es) 2018-08-22 2021-07-15 Cullgen Shanghai Inc Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk).
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
CN113874016A (zh) 2019-01-29 2021-12-31 福宏治疗公司 化合物及其用途
EP3923948A4 (en) 2019-02-12 2022-11-16 Impact Biomedicines, Inc. CRYSTALLINE SHAPES OF A JAK2 INHIBITOR
FR3092581A1 (fr) * 2019-02-12 2020-08-14 Impact Biomedicines, Inc Formes cristallines d'un inhibiteur de jak2
WO2020181232A1 (en) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
CN120172958A (zh) 2019-04-12 2025-06-20 C4医药公司 Ikaros和aiolos的三环降解物
JP2022533260A (ja) * 2019-05-24 2022-07-21 バイオセリックス, インコーポレイテッド タンパク質を標的とする化合物及びその医薬組成物並びにそれらの治療的応用
WO2021022163A2 (en) 2019-07-31 2021-02-04 Foghorn Therapeutics Inc. Compounds and uses thereof
TW202124374A (zh) * 2019-09-13 2021-07-01 美商拜歐斯瑞克斯公司 Ras蛋白降解劑、其醫藥組合物及其治療應用
AU2020387392B2 (en) 2019-11-19 2025-09-11 Bristol-Myers Squibb Company Compounds useful as inhibitors of Helios protein
BR112022011827A2 (pt) 2019-12-20 2022-08-30 C4 Therapeutics Inc Composto, composição farmacêutica, uso de um composto, métodos para tratamento ou profilaxia de câncer e para tratar um paciente com um distúrbio mediado por receptor do fator de crescimento epidérmico, e, invenção
AU2021214767A1 (en) 2020-01-29 2022-07-28 Foghorn Therapeutics Inc. Compounds and uses thereof
US12528825B2 (en) 2020-01-29 2026-01-20 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
CA3173262A1 (en) 2020-02-26 2021-09-02 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (trk) degradation compounds and methods of use
AU2021231898A1 (en) 2020-03-05 2022-10-27 C4 Therapeutics, Inc. Compounds for targeted degradation of BRD9
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
WO2022061348A1 (en) 2020-09-16 2022-03-24 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022072538A1 (en) * 2020-09-30 2022-04-07 Biotheryx, Inc. Antibody-drug conjugates, pharmaceutical compositions thereof, and their therapeutic applications
CN116583509A (zh) * 2020-10-07 2023-08-11 上海睿跃生物科技有限公司 治疗癌症的化合物和方法
WO2022087335A1 (en) 2020-10-23 2022-04-28 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
TW202237580A (zh) 2020-12-14 2022-10-01 美商拜歐斯瑞克斯公司 Pde4降解劑、醫藥組合物及治療應用
JP2024504932A (ja) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス, インコーポレイテッド イソインドリノン化合物
BR112023020077A2 (pt) 2021-04-06 2023-11-14 Bristol Myers Squibb Co Compostos de oxoisoindolina substituída por piridinila
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
WO2022261250A1 (en) 2021-06-08 2022-12-15 C4 Therapeutics, Inc. Therapeutics for the degradation of mutant braf
WO2023283263A1 (en) 2021-07-06 2023-01-12 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
US12419962B2 (en) 2022-03-16 2025-09-23 Biotheryx, Inc. Quinazolines, pharmaceutical compositions, and therapeutic applications
JP2025523393A (ja) 2022-06-06 2025-07-23 シーフォー セラピューティクス, インコーポレイテッド 二環式置換グルタルイミドセレブロンバインダー
CN120303264A (zh) * 2022-09-09 2025-07-11 医诺康治疗公司 CK1α和双重CK1α/GSPT1降解化合物
WO2024096753A1 (en) 2022-11-02 2024-05-10 Captor Therapeutics S.A. Nek7 degraders and methods of use thereof
CN120981456A (zh) 2023-05-24 2025-11-18 金橘生物科技公司 杂环化合物及其用途
AU2024307234A1 (en) 2023-06-30 2026-01-29 Kumquat Biosciences Inc. Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
WO2025096855A1 (en) 2023-11-02 2025-05-08 Kumquat Biosciences Inc. Degraders and uses thereof
WO2025240386A1 (en) * 2024-05-13 2025-11-20 Saint Joseph's University Allosteric agonists and positive allosteric modulators of glucagon-like peptide 1 receptor
WO2025261480A1 (zh) * 2024-06-21 2025-12-26 杭州中美华东制药有限公司 Gspt1降解剂化合物、包含其的药物组合物和用途

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378703A (en) 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
US5585377A (en) 1990-04-09 1996-12-17 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
US5153192A (en) 1990-04-09 1992-10-06 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors
DE4023048A1 (de) 1990-07-20 1992-01-23 Basf Ag Dicarbonsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
EP0625903B1 (en) 1992-02-21 1998-08-12 Alcon Laboratories, Inc. Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers
US5420923A (en) 1993-02-16 1995-05-30 Scientific-Atlanta, Inc. Addressed messaging in a cable television system
US5334596A (en) 1993-05-11 1994-08-02 Merck & Co., Inc. Fibrinogen receptor antagonists
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5605914A (en) 1993-07-02 1997-02-25 Celgene Corporation Imides
US5750471A (en) 1994-06-08 1998-05-12 E. I. Du Pont De Nemours And Company Cyclic sulfonamide herbicides
AU3619795A (en) 1994-10-11 1996-05-02 Takeda Chemical Industries Ltd. Substituted heterobicyclic alkyl amines and their use as squalene oxide cyclase inhibitors
ES2199348T4 (es) 1996-02-26 2010-10-19 ADVANCED RESEARCH & TECHNOLOGY INSTITUTE Uso de inhibidores de carbonico anhidrasa para el tratamiento del edema macular.
ZA98371B (en) 1997-01-31 1999-07-16 Du Pont Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides.
JPH10264532A (ja) 1997-03-24 1998-10-06 Fuji Photo Film Co Ltd 感熱記録材料
US6906245B1 (en) 1998-04-30 2005-06-14 Sumitomo Chemical Company, Limited Method for producing transgenic plants resistant to weed control compounds which disrupt the porphyrin pathways of plants
AU753020B2 (en) 1998-04-30 2002-10-03 Sumitomo Chemical Company, Limited Method for giving resistance to weed control compounds to plants
JP2000159761A (ja) 1998-11-30 2000-06-13 Yoshio Takeuchi フルオロサリドマイド
US6492380B1 (en) 1999-05-17 2002-12-10 Queen's University At Kingston Method of inhibiting neurotrophin-receptor binding
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
JP4821038B2 (ja) 1999-10-29 2011-11-24 住友化学株式会社 除草剤耐性植物
JP4821036B2 (ja) 1999-10-29 2011-11-24 住友化学株式会社 除草剤耐性植物
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
DE10133665A1 (de) 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
JP2004018434A (ja) 2002-06-14 2004-01-22 Mitsui Chemicals Inc 新規なフッ素化イミド化合物、および該化合物を用いた電子写真感光体、電子写真装置、有機電界発光素子
US7247736B2 (en) 2002-12-23 2007-07-24 4Sc Ag Method of identifying inhibitors of DHODH
MXPA05006890A (es) 2002-12-23 2006-04-07 4Sc Ag Compuestos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
CN100398534C (zh) 2003-09-15 2008-07-02 天津和美生物技术有限公司 合成酞胺哌啶酮及其衍生物的方法
SE0400970D0 (sv) 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
US8143257B2 (en) 2004-11-23 2012-03-27 Ptc Therapeutics, Inc. Substituted phenols as active agents inhibiting VEGF production
CN1939922B (zh) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3,4-c]吡咯-4,6-二酮衍生物
US8877780B2 (en) * 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
US7956064B2 (en) 2006-09-01 2011-06-07 Cylene Pharmaceuticals, Inc. Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators
WO2008045529A1 (en) 2006-10-12 2008-04-17 Serenex, Inc. Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases
CN101186611B (zh) * 2006-11-15 2011-05-18 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用
CN101186612B (zh) * 2006-11-15 2012-10-03 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用
EP1975165A1 (de) 2007-03-27 2008-10-01 Boehringer Ingelheim Pharma GmbH & Co. KG Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel
JP2008273924A (ja) 2007-03-30 2008-11-13 Meiji Seika Kaisha Ltd 2位チエニルカルバペネム誘導体
KR101128943B1 (ko) 2007-04-13 2012-03-27 주식회사 엘지화학 디옥시피롤기를 포함하는 헤테로고리 화합물 및 이를이용한 유기 전자 소자
JP2012505230A (ja) 2008-10-08 2012-03-01 ブリストル−マイヤーズ スクイブ カンパニー ピロロンメラニン凝集ホルモン受容体1拮抗薬
CN102271674A (zh) 2008-11-07 2011-12-07 4Sc股份公司 用于治疗自身免疫病的包含dhodh抑制剂和氨甲喋呤的联合治疗
EP2414340A1 (en) 2009-04-03 2012-02-08 Dainippon Sumitomo Pharma Co., Ltd. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
BR112013007499A2 (pt) 2010-09-01 2016-07-12 Genentech Inc piridazinonas - métodos de criação e usos
US20120085992A1 (en) 2010-09-30 2012-04-12 The Regents Of The University Of California Furan Conjugated Polymers Useful for Photovoltaic Applications
WO2012082893A2 (en) 2010-12-15 2012-06-21 Plextronics, Inc. Fluoro monomers, oligomers, and polymers for inks and organic electronic devices
US8921553B2 (en) 2011-04-15 2014-12-30 Georgia Tech Research-Corporation Stannyl derivatives of naphthalene diimides and related compositions and methods
ITMI20110881A1 (it) 2011-05-18 2012-11-19 E T C Srl Materiale semiconduttore organico
WO2013052153A1 (en) 2011-10-05 2013-04-11 Georgia Tech Research Corporation Blends of organic semiconductor compounds and electrically insulating amorphous polymers, methods and devices
JP2014047196A (ja) 2012-09-03 2014-03-17 Sumitomo Chemical Co Ltd 化合物及び高分子化合物、並びに、該化合物又は該高分子化合物を含有する有機半導体材料及び該有機半導体材料を用いた有機半導体素子
JP2014047192A (ja) 2012-09-03 2014-03-17 Sumitomo Chemical Co Ltd 化合物、並びに、該化合物を含有する有機半導体材料、有機半導体素子
CN103664916B (zh) 2012-09-12 2016-08-24 中国科学院化学研究所 基于联噻吩亚二吡咯及其衍生物的共轭小分子材料及其制备方法与应用
ITMI20121691A1 (it) 2012-10-09 2014-04-10 E T C Srl Materiale semiconduttore organico
ITMI20121939A1 (it) 2012-11-15 2014-05-16 E T C Srl Materiale organico semiconduttore
ITMI20121952A1 (it) 2012-11-16 2014-05-17 E T C Srl Materiale semiconduttore organico
WO2014089324A1 (en) 2012-12-07 2014-06-12 Calitor Sciences, Llc Substituted cyclic compounds and methods of use
JP2014185147A (ja) 2013-02-22 2014-10-02 Mitsubishi Chemicals Corp イミド縮合環化合物及びイミド縮合環化合物の製造方法
JP6248400B2 (ja) 2013-03-15 2017-12-20 株式会社リコー 感光体及び画像形成装置
JP2015013989A (ja) 2013-06-05 2015-01-22 三菱化学株式会社 コポリマー、半導体層形成用組成物、有機電子デバイス及び太陽電池モジュール
WO2014204082A1 (ko) 2013-06-20 2014-12-24 경상대학교산학협력단 유기 반도체 화합물, 이의 제조방법 및 이를 채용한 유기 태양전지
KR101595919B1 (ko) 2013-08-30 2016-02-29 한국과학기술연구원 전도성 유기 반도체 화합물 및 이를 포함하는 유기태양전지
US9809594B2 (en) 2013-09-10 2017-11-07 University Of Washington Through Its Center For Commercialization Non-fullerene electron acceptors for organic photovoltaic devices
KR101732220B1 (ko) 2014-03-31 2017-05-02 주식회사 엘지화학 헤테로환 화합물 및 이를 포함하는 유기 태양 전지
CN105294536B (zh) 2014-06-30 2018-06-29 中国科学院上海有机化学研究所 一种制备3-亚氨基异吲哚啉酮类化合物的方法
KR20170042598A (ko) * 2014-08-22 2017-04-19 셀진 코포레이션 항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법
CN104230953B (zh) 2014-08-25 2016-08-17 中国科学院上海有机化学研究所 含2-(1,3-二硫/硒-2-亚基)乙氰共轭结构单元的萘二酰亚胺及其衍生物
WO2016061751A1 (en) 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors
CN105693745B (zh) 2014-11-27 2019-07-05 中国科学院苏州纳米技术与纳米仿生研究所 有机π-共轭化合物、其制备方法及应用
AU2016266942B2 (en) 2015-05-22 2018-10-18 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
CA3043938A1 (en) * 2016-12-21 2018-06-28 Biotheryx, Inc. Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof

Also Published As

Publication number Publication date
IL267323A (en) 2019-08-29
TW201835089A (zh) 2018-10-01
MX387646B (es) 2025-03-18
KR20190093205A (ko) 2019-08-08
US10040804B2 (en) 2018-08-07
US20190322683A1 (en) 2019-10-24
TWI756957B (zh) 2022-03-01
RU2771166C2 (ru) 2022-04-27
RU2019115392A3 (https=) 2021-05-14
ZA201903479B (en) 2021-09-29
RU2019115392A (ru) 2021-01-22
MX2019007434A (es) 2019-08-16
TW202120514A (zh) 2021-06-01
US20210139500A1 (en) 2021-05-13
EP3559005A1 (en) 2019-10-30
AU2017382176A1 (en) 2019-05-30
US20180170948A1 (en) 2018-06-21
US20180298027A1 (en) 2018-10-18
US10889593B2 (en) 2021-01-12
US11345714B2 (en) 2022-05-31
CN110099907A (zh) 2019-08-06
JP2020504711A (ja) 2020-02-13
US10336771B2 (en) 2019-07-02
WO2018118947A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
US11345714B2 (en) Compounds targeting proteins, compositions, methods, and uses thereof
US10857155B2 (en) Compounds targeting proteins, compositions, methods, and uses thereof
US10562917B2 (en) Chimeric compounds targeting proteins, compositions, methods, and uses thereof
CA3101335C (en) Fused thiophene compounds
CA3101338A1 (en) Aminoamide compounds
IL255589A (en) Compounds targeting proteins, preparations, methods and uses
CN113423701A (zh) 取代的异吲哚啉酮
CA3094988A1 (en) Thienopyrimidinone compounds
WO2019173224A1 (en) Deuterated compounds and chimeras and uses thereof
KR20180050408A (ko) 국부 약물 전달용의 비스테로이드성 글루코코르티코이드 수용체 조절제

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211123

FZDE Discontinued

Effective date: 20240501